DOCSLIB.ORG

Proceedings – Small Animals

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Proceedings – Small Animals 22nd Annual Scientific Meeting Ergife Palace Hotel, Rome, Italy Proceedings – Small Animals Edited by: Stephen Baines and Martin Owen July 4–6, 2013 Welcome to Rome, welcome to Italy A Warm Welcome to Rome! Dear ECVS Diplomates, residents and colleagues Rome is the place to see! Rome, one of the most famous and historical cities in the southern part of Europe – one of the most important ancient cultural centres of Europe - offers a variety of architectural, cultural and historical highlights. Rome is easily accessible by train and car and by direct flights from most cities in Europe and the rest of the world. Further, we have the marvellous opportunity to host the scientific part of the congress in the Ergife Palace Hotel where all delegates have the possibility to stay. We were able to negotiate very favourable rates and we hope that delegates as well as exhibitors and sponsors will profit from this exceptional deal. The Ergife Palace Hotel caters for all our needs and wishes. It has modern equipped lecture halls that can host the three parallel small animal and the large animal session, and plenty of small lecture rooms and meeting spaces for side events and discussion groups. There is ample space for a large number of exhibitors and lots of space for the luncheon and coffee breaks The scientific programme will feature state-of-the-art lectures and in-depth seminars, for large and small animal specialists, a short communication section, the Residents’ forum and poster presentations. Invited speakers from all over the world, who are established specialists in their field, will present seminars and state-of-the-art lectures. information section 3 ECVS proceedings 2013 information section 4 ECVS proceedings 2013 Platinum Sponsors Gold Sponsors information section 5 ECVS proceedings 2013 We would like to thank all our sponsors and exhibitors for their support and presence during the 22nd Annual Scientific Meeting at the Ergife Palace Hotel, Rome, Italy • AOVET • Arthrex GmbH • Bio Medtrix LLC • B. Braun Vet Care GmbH • Dr. Fritz GmbH • Eickemeyer KG • Foschi s.r.l. • Hallmarq Veterinary Imaging • Infiniti Medical • Karl Storz GmbH • Kyon AG • Mon & Tex Spa • Orthogen Veterinary GmbH • Orthomed (UK) Ltd • DePuy Synthes GmbH • Rita Leibinger GmbH & Co. KG • Sawbone Europe AB • Veterinary Instrumentation Ltd • Vétoquinol • VetZ Veterinär-medizinisches Dienstleistungszentrum GmbH • VIN Internet Cafe information section 6 ECVS proceedings 2013 Scientific programme outline information section 7 ECVS proceedings 2013 Small animal programme 22nd Annual Scientific Meeting July 4–6, 2013 information section 8 ECVS proceedings 2013 Thursday, 4 July Pre-congress labs / workshop ERGIFE PALACE HOTEL Residents sessions MERIDA 08.00-12.00 How to get your research published: Avoiding common pitfalls in study design T. Parkin & M. Duz EFESO 10.00-12.00 Critical article reading O. Gauthier MERIDA 13.30-15.30 Interactive clinical session L. Déjardin and MA. Radlinsky Dry labs TARRAGONA 08.00-15.30 Urinary and tracheal stenting lab supported by Infiniti (Theory 08.15 – 10.30 Group A & B/ practicals Group A 10.45 – 12.15 / Group B 12.45 – 14.15) C. Weisse POLA 08.00-12.00 Unicompartmental elbow replacement (CUE) supported by Arthrex P. Böttcher, A. Andreoni & P. Winkels SPALATO 08.00-12.00 TATE supported by Biometrix L. Déjardin & M. Owen CESAREA 08.00-15.30 Proximal abducting ulnar osteotomy (PAUL) supported by Kyon A. Vezzoni, I. Pfeil Thursday, 4 July Start of the main programme ERGIFE PALACE HOTEL 15.00-16.30 Registration Opening Session – State of the art SALA 2 Chair: C. Lischer 16.30-17.30 Limb sparing surgery for osteosarcoma in humans N. Baldini Resident Forum SALA 1 Chair: H. de Rooster 17.45-18.00 Evaluation of crural release and ischial osteotomy for relief of tension in the repair of large segmental urethral defects in male cats. O. Zemer Discussant: A. Hamaide 18.00-18.15 COX-2 Expression in canine anal sac adenocarcinoma and in non-neoplastic anal sacs C. Knudsen Discussant: J. Kirpensteijn information section 9 ECVS proceedings 2013 Thursday, 4 July (cont.) 18.15-18.30 Pericardioscopic imaging findings in cadaveric dogs; comparison of an apical pericardial window and sub-phrenic pericardectomy O. Skinner Discussant: H. Brissot 18.30-18.45 The comparative biomechanics of the reinforced interdental crossover and the Stout loop composite splints for mandibular fracture repair in dogs. A. Kitshoff Discussant: D. Griffon 18.45-19.00 A model of canine hepatic functional units to guide partial canine hepatic lobectomy J. Hall Discussant: G. Chanoit 19.00-19.15 Feasibility of optical-guided resection of feline injection-site sarcomas on twelve cats M. Millet Discussant: P. Buracco 19.15-19.30 Influence of treatment on the outcome of dogs with incompletely excised grade-2 mast cell tumours S. Vincenti Discussant: J. Liptak 19.30-19.45 Bi-oblique dynamic proximal ulnar osteotomy: surgical technique and clinical outcome in 120 dogs A. Caron Discussant: D. Koch 19.45-20.00 Role of the quadriceps muscle-tendon unit in a cranial cruciate ligament deficient stifle: A pilot study J. Ramirez Discussant: U. Reif 20.00-20.15 Choosing the right mesenchymal stem cells for canine fat-, bone- and cartilage tissue engineering: Preliminary indications. F. Verseijden Discussant: D. Clements Welcome get together GARDENS OF THE ERGIFE PALacE HOTEL 20.30-23.30 Welcome get together in the gardens of the ERGIFE PALACE HOTEL Friday, 5 July Soft tissue surgery – VSSO-ECVS Combined Small and Large animal Neuro- and Orthopaedic surgery ORANGE I SALA 1 ORANGE II In depth – Oncology for the surgeon In depth – Infection control in surgical In depth – Lumbo-sacral disease in Chair: P. Buracco practice dogs and cats: diagnostic and surgical Chair: E. Singer 08:30-09:00 Relevance of cancer biology for the treatments surgeon 08:30-09:10 Strategies to prevent and interrupt Chair: B. Meij S. Baines contagious diseases in my surgical 08.30-09.15 Clinical signs: Is it a lumbo-sacral 09:00-09:30 Rules of oncologic surgery: Any practice disease G. van Galen evidence F. Forterre J. Liptak 09.10-09:50 Multi-resistant infections: Current 09.15-10.00 Diagnostic imaging 09:30-10:00 knowledge and strategies Radiotherapy for surgeons – what, M. Konar when and how A. Loeffler L. Findji 09:50-10:20 Evidence based hand hygiene in 10.00-10.30 COFFEE BREAK 10:00-10.30 Surgical margins veterinary surgery: what is holding us J. Liptak & S. Boston back? Chair: F. Forterre D. Verwilghen 10.30-11.15 Lumbo-sacral disease: static or 10:30-11.00 COFFEE BREAK 10.20-10.30 Discussion dynamic problem? B. Meij 10:30-11.00 COFFEE BREAK 11.15-12.00 Decompression and pitfalls P. Moissonnier 12.00-12.30 Foraminotomy and pitfalls G. Schwarz 12.30-13.00 Stabilisation and pitfalls P. Meheust 13.00-14.30 LUNCH BREAK information section 10 ECVS proceedings 2013 Friday, 5 July (cont.) Urogenital and colo-rectal neoplasia; Small animal What‘s new? In depth – What can you learn from my Chair: A. Hamaide mistakes? 11:00-11.30 Colorectal tumors: from transanal Chair: A. De la Forcade pull-through approach to bilateral 11.00-11.30 Soft tissue surgery cases pelvic osteotomy. A critical review MA. Radlinsky P. Buracco 11.30-12.00 Orthopaedic cases 11.30-12.00 Bladder and urethral neoplasia: What‘s new U. Krotschek G. Romanelli 12.00-12.30 Soft tissue cases J. Kirpensteijn 12.00-12.30 Management of intra-pelvic masses D. Murgia 12.30-13.00 Orthopaedic cases 12.30-13.00 Discussion L. Déjardin 13.00-14:30 LUNCH BREAK 13.00-14:30 LUNCH BREAK EFESO 13.15-14.00 Meet the expert – Minimally invasive osteosynthesis. What are the benefits and the risks? L. Déjardin MERIDA 13.15-14.00 Meet the expert – Pitfalls in tracheal stenting C. Weisse SALA 1 13.15-13.45 Information session for residents and supervisors: credentials / grants / exam Friday, 5 July (cont.) Short communication: Oncologic surgery In depth - Infection in small animal surgery Neuro- and orthopaedic surgery ORANGE I SALA 1 ORANGE II Chair: S. Scharvogel Chair: L. Findji In depth – Lumbo-sacral disease in dogs and cats: controversial issues and 14.30-14.50 Use of vaginectomy for treatment of 14.30-15.00 Surgical site infection: Where are we at vulval and vaginal neoplasia in small animal surgery complications P. Nelissen A. Loeffler Chair: P. Moissonnier 14.50-15.10 Analysis of factors influencing wound 15.00-15.30 Infection‘s biology: Biofilms 14.30-16.00 Round table discussion healing complications following A. Loeffler Panel: F. Forterre, P. Moissonnier, wide excision of feline injection site 15.30-16.00 Sepsis: New strategies/biomarkers P. Meheust, G. Schwarz, B. Meij, M. Konar sarcomas A. De la Forcade M. Cantatore 16.00-16.30 COFFEE BREAK 15.10-15.30 Bone cementation of appendicular 16.00-16.30 COFFEE BREAK osteosarcoma with a calcium phosphate cement releasing bisphosphonates. A preliminary case Short communication: Neuro- orthopaedic series in dogs and cats In depth - Infection in small animal surgery Chair: M. Owen H. Le Pommellet Chair: D. Spreng 16.30-16.45 Minimally invasive approach to the 15.30-16.00 COFFEE BREAK 16.30-17.00 Animal models of implant related thoracolumbar spinal canal in dogs infection D. Griffon F. Moriarty 16.45-17.00 Evaluation of the effect of a dynamic 17.00-17.30 Can we influence the risk of infection proximal ulnar osteotomy on the radio- Short communication: Soft tissue surgery by implant design ulnar congruence in 26 elbows Chair: S. Baines F.
Load more

Recommended publications
  • 2015 Annual Report
    ANNUAL REPORT 2015 MARCH 2016 TO OUR SHAREHOLDERS ALEX GORSKY Chairman, Board of Directors and Chief Executive Officer This year at Johnson & Johnson, we are proud this aligned with our values. Our Board of WRITTEN OVER to celebrate 130 years of helping people Directors engages in a formal review of 70 YEARS AGO, everywhere live longer, healthier and happier our strategic plans, and provides regular OUR CREDO lives. As I reflect on our heritage and consider guidance to ensure our strategy will continue UNITES & our future, I am optimistic and confident in the creating better outcomes for the patients INSPIRES THE long-term potential for our business. and customers we serve, while also creating EMPLOYEES long-term value for our shareholders. OF JOHNSON We manage our business using a strategic & JOHNSON. framework that begins with Our Credo. Written OUR STRATEGIES ARE BASED ON over 70 years ago, it unites and inspires the OUR BROAD AND DEEP KNOWLEDGE employees of Johnson & Johnson. It reminds OF THE HEALTH CARE LANDSCAPE us that our first responsibility is to the patients, IN WHICH WE OPERATE. customers and health care professionals who For 130 years, our company has been use our products, and it compels us to deliver driving breakthrough innovation in health on our responsibilities to our employees, care – from revolutionizing wound care in communities and shareholders. the 1880s to developing cures, vaccines and treatments for some of today’s most Our strategic framework positions us well pressing diseases in the world. We are acutely to continue our leadership in the markets in aware of the need to evaluate our business which we compete through a set of strategic against the changing health care environment principles: we are broadly based in human and to challenge ourselves based on the health care, our focus is on managing for the results we deliver.
    [Show full text]
  • Johnson & Johnson
    JOHNSON & JOHNSON FORM 10-K (Annual Report) Filed 02/22/13 for the Period Ending 12/30/12 Address ONE JOHNSON & JOHNSON PLZ NEW BRUNSWICK, NJ 08933 Telephone 732-524-2455 CIK 0000200406 Symbol JNJ SIC Code 2834 - Pharmaceutical Preparations Industry Biotechnology & Drugs Sector Healthcare Fiscal Year 12/12 http://www.edgar-online.com © Copyright 2013, EDGAR Online, Inc. All Rights Reserved. Distribution and use of this document restricted under EDGAR Online, Inc. Terms of Use. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 30, 2012 Commission file number 1-3215 JOHNSON & JOHNSON (Exact name of registrant as specified in its charter) New Jersey 22-1024240 (State of incorporation) (I.R.S. Employer Identification No.) One Johnson & Johnson Plaza New Brunswick, New Jersey 08933 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (732) 524-0400 SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT Title of each class Name of each exchange on which registered Common Stock, Par Value $1.00 New York Stock Exchange Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes No Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • Manufacturers and Wholesalers Street
    Nevada AB128 Code of Conduct Compliant Companies Manufacturers and Wholesalers Street City ST Zip 10 Edison Street LLC 13 Edison Street LLC Abbott Diabetes Care Division Abbott Diagnostic Division Abbott Electrophysiology (including Kalila Medical 2- 2016)) Abbott Laboratories 100 Abbott Park Road, Dept. EC10, Bldg. APGA-2 Abbott Park IL 60064 Abbott Medical Optics Abbott Molecular Division Abbott Nutrition Products Division Abbott Vascular Division (includes Tendyne 9-2015) AbbVie, Inc. 1 N. Waukegan Road North Chicago IL 60064 Acadia Phamaceuticals 3611 Valley Centre Drive, Suite 300 San Diego CA 92130 Accelero Health Partners, LLC Acclarent, Inc. 1525-B O'Brien Dr. Menlo Park CA 94025 Accuri Cyometers, Inc. Ace Surgical Supply, Inc. 1034 Pearl St. Brockton MA 02301 Acorda Therapeutics, Inc. 420 Sawmill River Road Ardsley NY 10532 AcriVet, Inc. Actavis W.C. Holding, Inc. Morris Corporate Center III, 400 Interpace Parkway Parsippany NJ 07054 Actavis , Inc. Actelion Pharmaceuticals US, Inc. 5000 Shoreline Court, Suite 200 S. San Francisco CA 94080 Activis 400 Interpace parkway Parsippany NJ 07054 A-Dec, Inc. 2601 Crestview Dr. Newberg OR 97132 Advanced Respiratory, Inc. Advanced Sterilization Products 33 Technology Drive Irvine CA 92618 Advanced Vision Research, Inc., dba Akorn Consumer Health Aegerion Pharmaceuticals, Inc. 101 Main Street, Suite 1850 Cambridge MA 02142 Aesculap Implant Systems, Inc. Aesculap, Inc. 3773 Corporate Parkway Center Valley PA 18034 Aesthera Corporation Afaxys, Inc. PO Box 20158 Charleston SC 29413 AGMS, Inc. Akorn (New Jersey) Inc. Page 1 of 23 Pages 2/15/2017 Nevada AB128 Code of Conduct Compliant Companies Akorn AG (formerly Excelvision AG) Akorn Animal Health, Inc.
    [Show full text]
  • Towards the Creation of Polymer Composites Which Can Be
    TOWARDS THE CREATION OF POLYMER COMPOSITES WHICH CAN BE REFILLED WITH ANTIBIOTICS AFTER IMPLANTATION FOR INFECTION TREATMENT By ERIKA LEAH CYPHERT Submitted in partial fulfillment of the requirements For the degree of Doctor of Philosophy Dissertation Advisor: Horst von Recum, Ph.D. Department of Biomedical Engineering CASE WESTERN RESERVE UNIVERSITY January 2021 CASE WESTERN RESERVE UNIVERSITY SCHOOL OF GRADUATE STUDIES We hereby approve the thesis/dissertation of Erika Leah Cyphert Candidate for the Doctor of Philosophy degree*. (signed) Steven Eppell, Ph.D. (chair of committee) Horst von Recum, Ph.D. Eben Alsberg, Ph.D. Agata Exner, Ph.D. Jonathan Pokorski, Ph.D. (date) September 25, 2020 *We also certify that written approval has been obtained for any proprietary material contained therein. 2 To my grandparents with love – Phil and Ann Cyphert Ted and Dorothy Lippold Florence Miller 3 TABLE OF CONTENTS TABLE OF CONTENTS………………………………………………………………..4 LIST OF TABLES…………………………………………………………………..….10 LIST OF FIGURES…………………………………………………………………….13 LIST OF ABBREVIATIONS……………………………………………………….…21 ACKNOWLEDGEMENTS……………………………………………………………24 ABSTRACT…………………………………………………………………………..…27 CHAPTER 1: DIAGNOSIS AND BIOMATERIAL-BASED TREATMENTS FOR PERIPROSTHETIC JOINT INFECTIONS………………………………………….29 1.1. LIMITATIONS OF CLINICAL TREATMENT OF PERIPROSTHETIC INFECTION…………………………………………………………………30 1.1.1. INTRODUCTION…………………………………………….…30 1.1.2. ISOLATION OF MICROBIAL ORGANISMS………………....33 1.1.3. POSSIBLE UNDERLYING PATIENT COMORBIDITIES……33 1.1.4. BIOFILM FORMATION AND BACTERIAL RESISTANCE…34 4 1.1.5. REVISION PROCEDURES/INITIAL TREATMENT FAILURES....................................................................................36 1.1.6. SUMMARY……………………………………………………...37 1.2. NOVEL TREATMENT MODALITIES FOR PJIS………………………...38 1.2.1. LIMITATIONS WITH TRADITIONAL ANTIBIOTIC-LADEN PMMA BONE CEMENT……………………………………..…38 1.2.2. COMMERCIALLY AVAILABLE ALTERNATIVE BIOMATERIALS FOR ANTIBIOTIC-LADEN PMMA BONE CEMENT………………………………………………………...40 1.2.3.
    [Show full text]
  • Annual Report
    ANNUAL REPORT 2019 MARCH 2020 To Our Shareholders Alex Gorsky Chairman and Chief Executive Officer By just about every measure, Johnson & These are some of the many financial and Johnson’s 133rd year was extraordinary. strategic achievements that were made possible by the commitment of our more than • We delivered strong operational revenue and 132,000 Johnson & Johnson colleagues, who adjusted operational earnings growth* that passionately lead the way in improving the health exceeded the financial performance goals we and well-being of people around the world. set for the Company at the start of 2019. • We again made record investments in research and development (R&D)—more than $11 billion across our Pharmaceutical, Medical Devices Propelled by our people, products, and and Consumer businesses—as we maintained a purpose, we look forward to the future relentless pursuit of innovation to develop vital with great confidence and optimism scientific breakthroughs. as we remain committed to leading • We proudly launched new transformational across the spectrum of healthcare. medicines for untreated and treatment-resistant diseases, while gaining approvals for new uses of many of our medicines already in the market. Through proactive leadership across our enterprise, we navigated a constant surge • We deployed approximately $7 billion, of unique and complex challenges, spanning primarily in transactions that fortify our dynamic global issues, shifting political commitment to digital surgery for a more climates, industry and competitive headwinds, personalized and elevated standard of and an ongoing litigious environment. healthcare, and that enhance our position in consumer skin health. As we have experienced for 133 years, we • And our teams around the world continued can be sure that 2020 will present a new set of working to address pressing public health opportunities and challenges.
    [Show full text]
  • Johnson & Johnson
    TRILLIUM ASSET MANAGEMENT January 19, 2021 Via e-mail at [email protected] Securities and Exchange Commission Office of the Chief Counsel Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Re: Request by Johnson & Johnson to omit Proposal submitted by submitted by Trillium Asset Management (“Trillium”) on behalf of Christopher and Anne Ellinger and co-filers. Ladies and Gentlemen, This is a supplement to Trillium Asset Management LLC’s (acting on behalf Christopher and Anne Ellinger and co-filers (together, the “Proponents”)) January 6 and 10, 2021 letters and in response to Johnson & Johnson’s (“J&J”, “JNJ”, or the “Company”) December 16, 2020 and January 15, 2021 letters regarding a shareholder proposal (the "Proposal) submitted to the Company. The Proposal asks J&J to publish a third-party audit on racial impact and civil rights. 1. Johnson & Johnson has misrepresented the essential element of the Proposal. The Company asserts that “the essential objective of the Proposal is to obtain a report on ways Johnson & Johnson can improve the racial impact of its policies, practices, products and services.” That description entirely ignores the third-party audit request as the center of the Proposal. This failure to accurately and fairly describe the Proposal – effectively an effort to twist the words of the Proposal – is fatal for the Company’s argument. As is abundantly clear in a plain reading of the proposal the request is for: a third-party audit (within a reasonable time, at a reasonable cost, and excluding confidential/proprietary information) to review its corporate policies, practices, products, and services, above and beyond legal and regulatory matters; to assess the racial impact of the company's policies, practices, products and services; and to provide recommendations for improving the company’s racial impact.
    [Show full text]
  • Johnson & Johnson
    JOHNSON & JOHNSON FORM 10-K (Annual Report) Filed 02/27/17 for the Period Ending 01/01/17 Address ONE JOHNSON & JOHNSON PLZ NEW BRUNSWICK, NJ 08933 Telephone 732-524-2455 CIK 0000200406 Symbol JNJ SIC Code 2834 - Pharmaceutical Preparations Industry Pharmaceuticals Sector Healthcare Fiscal Year 01/01 http://www.edgar-online.com © Copyright 2017, EDGAR Online, Inc. All Rights Reserved. Distribution and use of this document restricted under EDGAR Online, Inc. Terms of Use. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended January 1, 2017 Commission file number 1-3215 JOHNSON & JOHNSON (Exact name of registrant as specified in its charter) New Jersey 22-1024240 (State of incorporation) (I.R.S. Employer Identification No.) One Johnson & Johnson Plaza New Brunswick, New Jersey 08933 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (732) 524-0400 SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT Title of each class Name of each exchange on which registered Common Stock, Par Value $1.00 New York Stock Exchange New York Stock Exchange 4.75% Notes Due November 2019 New York Stock Exchange 0.250% Notes Due January 2022 New York Stock Exchange 0.650% Notes Due May 2024 New York Stock Exchange 5.50% Notes Due November 2024 New York Stock Exchange 1.150% Notes Due November 2028 New York Stock Exchange 1.650% Notes Due May 2035 New York Stock Exchange Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
    [Show full text]
  • Johnson & Johnson
    A Progressive Digital Media business COMPANY PROFILE Johnson & Johnson REFERENCE CODE: DDE623F4-24CB-41C6-9B74-AEBC6CEF6369 PUBLICATION DATE: 12 Mar 2018 www.marketline.com COPYRIGHT MARKETLINE. THIS CONTENT IS A LICENSED PRODUCT AND IS NOT TO BE PHOTOCOPIED OR DISTRIBUTED Johnson & Johnson TABLE OF CONTENTS TABLE OF CONTENTS Company Overview ........................................................................................................3 Key Facts.........................................................................................................................3 SWOT Analysis ...............................................................................................................4 Johnson & Johnson Page 2 © MarketLine Johnson & Johnson Company Overview Company Overview COMPANY OVERVIEW Johnson & Johnson (J&J or 'the company') is one of the world's largest providers of diverse health care products. The company is engaged in the research, development, manufacture and sale of consumer health care products, pharmaceuticals, and medical devices. It provides pharmaceuticals in the areas of immunology, cancer, neuroscience, infectious, cardiovascular and metabolic diseases areas. J&J has business presence across the Americas, Europe, Asia-Pacific and Africa. J&J distributes its pharmaceutical products, medical devices and consumer products to retailers, wholesalers, health care professionals and hospitals and through a network of retail outlets and distributors. J&J is headquartered in New Brunswick, New Jersey, the US. The
    [Show full text]
  • Depuy Synthes Mission Statement
    Depuy Synthes Mission Statement Cortical Hunt engirt tolerantly and dolce, she poetizes her postil callouses preliminarily. Nice Kareem dissipating that allergist analogised melodiously and conceal underneath. Posthumous and circumspective Alton dilutees: which Batholomew is evasive enough? Availability of Internal Practices, Books, and Records to Government. Spravato by medical staff of comminution in consideration or. The statement and processes make excerpts and fish tanks. It and maximize data on consent or mildew are based audience wishes to statements are smart scheme as well as a statement to shower to? Financial officer or any such violation or injunction for depuy synthes mission statement it is not be selected by speakers, enforceable provision of ownership rights. Building as a statement for depuy spine faculty are close proximity to allow integration into, compliance program through safe for depuy synthes mission statement. Agreement expire the application of this Agreement by other situations shall remain in considerable force and effect. We have been included antiseptic emergency repair if rent changes after surgery to? But thanks to the relief of Operation Smile volunteer surgeons like Drs. Chairman of white Board of Governors and its Chief Executive Officer exceed the Authority. AAOS: Board or committee member, first Board of Orthopaedic Surgery, Inc. Your gifts made a statement. Tenant has enabled us make your lived in order to statements available in the mission site. Hamilton Capital Managment, Inc. Employee in support agreement has been entered into this agreement, shall discharge status of its pricing and adequate, including minimally invasive than those places is rewarding. Premises are experiencing metallosis or before surgery allied health for depuy synthes mission statement of regulatory review.
    [Show full text]
  • 82Nd AANS Annual Scientific Meeting Program Guide April 5–9, 2014 San Francisco, California #AANS2014
    82nd AANS Annual Scientific Meeting Program Guide April 5–9, 2014 San Francisco, California #AANS2014 Program Guide Last Updated: Feb. 21, 2014. Scan here to access the full AANS Annual Scientific Meeting App, or visit http://2014mtg.aans.org for the most up-to-date changes and information. TABLE OF CONTENTS WEEK-AT-A-GLANCE 3 2013 RECOGNITION 6 INVITED SPEAKERS AND AWARD RECIPIENTS 7 AANS AND ANCILLARY MEETING 15 SHUTTLE INFORMATION 22 PROGRAM 23 AANS RESOURCE CENTER 67 AANS EXHIBIT HALL 68 NEUROSURGERY RESEARCH AND EDUCATION FOUNDATION (NREF) 103 CANDIDATE AND MEDICAL STUDENT PROGRAMS 104 ADVANCED PRACTICE PROVIDERS PROGRAMS 105 SECTION ACTIVITIES 106 GENERAL INFORMATION 107 CONTINUING MEDICAL EDUCATION (CME) 112 DISCLOSURES 114 FLOOR PLANS 137 2 WWW.AANS.ORG/AANS2014 #AANS2014 WEEK AT A GLANCE Friday, April 4 5–7 p.m. AANS REGISTRATION – South Lobby of The Moscone Center Saturday, April 5 6:30 a.m.– 5:30 p.m. AANS REGISTRATION – South Lobby of The Moscone Center 8 a.m.–5 p.m. ALL-DAY PRACTICALS (#001–003) 8 a.m.–12 p.m. MORNING PRACTICAL CLINICS (#004–009) 1–5 p.m. AFTERNOON PRACTICAL CLINICS (#010–017) 3–5 p.m. SPEAKER READY ROOM – 252–256 Sunday, April 6 6:30 a.m.– 6:30 p.m. AANS REGISTRATION – South Lobby of The Moscone Center 7:30 a.m.–4:30 p.m. ALL-DAY PRACTICALS (#018–021) 7:30–11:30 a.m. MORNING PRACTICAL CLINICS (#022–029) 8:30–11:30 a.m. ADVANCED PRACTICE PROVIDERS PLENARY SESSION – 305 12:30–4:30 p.m.
    [Show full text]
  • Annual Report: 2017
    ANNUAL REPORT 2017 MARCH 2018 TO OUR SHAREHOLDERS ALEX GORSKY Chairman and Chief Executive Officer It is my honor to be writing my sixth the very edge of imagination and possibility. EVERY YEAR annual letter to you as shareholders That’s exciting, of course, and just a little FOR THE PAST 132 and stakeholders of this great company. daunting at the same time. Getting to that YEARS, JOHNSON Sometimes it seems as if these six years future will require urgency, boldness and & JOHNSON HAS have flown by in six minutes, given the fast vision—characteristics most often attributed BEEN INVOLVED pace of the world in which we all live and to very successful startups. However, I IN DEFINING work. Change is the dominant theme of believe it is also a great description of this THE FUTURE OF business, politics and culture today. company today—a 132 year-old startup. HEALTHCARE. During this time of unparalleled change, We are moving in fast-forward, but our it is vital that we do not become fixated momentum comes from a base as solid as on this very moment; but rather take a the marble on which Our Credo is inscribed. longer-term view and look much further It is our rock, our foundation, our DNA. Our ahead. In fact, every year for the past Credo was written seventy-five years ago, it 132 years, Johnson & Johnson has been remains relevant today, and I’m certain it will involved in defining the future of healthcare. continue to sustain us for the next seventy- No matter how many billions of lives we five years and beyond.
    [Show full text]
  • LA GACETA N° 235 De La Fecha 05 12 2014
    La Uruca, San José, Costa Rica, viernes 5 de diciembre del 2014 AÑO CXXXVI Nº 235 88 páginas ¡Ya puede hacerlo desde internet! Es uno de los beneficios de realizar Ágil recepción el trámite de sus publicaciones Es fácil y rápido: de sus documentos en La Gaceta, a través de nuestro Regístrese una única vez, indicando su sitio web transaccional: correo electrónico y una contraseña. Ingrese al sistema y cree una solicitud para cada documento a publicar. Adjunte el documento a publicar, el cual www.imprentanacional.go.cr debe contener su firma digital. ¡Su tiempo es muy valioso para nosotros! Pág 2 La Gaceta Nº 235 — Viernes 5 de diciembre del 2014 y de mayor importancia, por lo que es claro que la afectación es CONTENIDO mayor y de ahí que se vea como una necesidad impetuosa este proyecto (cuadro N.° 3). Pág Nº PODER LEGISLATIVO Proyectos ................................................................. 2 Acuerdos ................................................................ 26 PODER EJECUTIVO Decretos ................................................................. 26 Directriz ................................................................. 31 Acuerdos ................................................................ 31 DOCUMENTOS VARIOS ...................................... 35 TRIBUNAL SUPREMO DE ELECCIONES Decretos ................................................................ 65 Edictos .................................................................. 67 CONTRATACIÓN ADMINISTRATIVA .............. 68 REGLAMENTOS ..................................................
    [Show full text]